Last $0.18 USD
Change Today -0.001 / -0.54%
Volume 214.3K
AVXL On Other Exchanges
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/10/13 - $0.67
52 Week Low
09/30/14 - $0.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a pharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and various cancers. Its lead drug candidates include ANAVEX 2-73, which has completed Phase I single ascending dose clinical trial for the treatment of Alzheimer’s disease; and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept) for Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is highly effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037 for the treatment of prostate cancer. The company was founded in 2006 and is based in New York, New York.

1 Employees
Last Reported Date: 08/6/14
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2013.

anavex life sciences corp (AVXL) Key Developments

Anavex Reports Antidepressant Fluvoxamine Reduces Stress Through Sigma-1 Receptor

Anavex Life Sciences Corp. announced new data published in the current issue of Cell Death and Disease that the commonly used selective serotonin reuptake inhibitor (SSRI) Fluvoxamine has a high affinity for sigma-1 receptor (S1R) and thus can alleviate cell stress. The scientific findings indicate that Fluvoxamine, which is marketed for depression, obsessive-compulsive disorder (OCD) and panic disorder, prevents neuronal cell death resulting from endoplasmic reticulum (ER) stress through induction of S1R. Disturbances in neuron regulations could cause ER stress, a state in which the folding of proteins slows, leading to an increase in unfolded proteins. This stress is emerging as a potential cause of damage in neuronal disorders including Alzheimer's disease. Therefore, S1R expression may have an important role in synapse formation and plasticity. Thus, it is possible that Fluvoxamine's cellular responses to ER stress could contribute not only to pathological conditions, but also to normal neural development.

Anavex Life Sciences Corp. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

Anavex Life Sciences Corp. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, operating loss was $998,833 against $125,982 a year ago. Net loss was $1,009,090 or $0.03 per basic and diluted share against $151,924 or $0.01 per basic and diluted share a year ago. For the nine months, operating loss was $2,329,608 against $668,960 a year ago. Net loss was $1,669,313 or $0.06 per basic and diluted share against $711,541 or $0.02 per basic and diluted share a year ago.

Anavex Life Sciences Corp. Appoints Tasos Zografidi as Vice President of Clinical Operations

Anavex Life Sciences Corp. announced the appointment of Tasos Zografidis, PhD as Vice President, Clinical Operations. In this newly created position, Dr. Zografidis will be responsible for managing Anavex's clinical programs, including the upcoming Phase 2a clinical trial for ANAVEX 2-73 and ANAVEX PLUS, the company's lead drug candidate combination in Alzheimer's disease. Dr. Zografidis prior to joining Anavex most recently served as clinical and pharmaceutical consultant. He has been involved in more than a dozen clinical trials and has co-authored numerous publications. Dr. Zografidis first joined Wyeth in 1998 as a Product Manager. During his tenure until 2010, he had increased responsibility as Medical Liaison for the transplantation, haemophilia and oncology divisions where he was instrumental in driving sales in assigned European territories.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.18 USD -0.001

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at